Abstracts tagged "polyarteritis nodosa and vasculitis"

Abstract Number: 1702 • 2019 ACR/ARP Annual Meeting
Target Organ Associations in Polyarteritis Nodosa (PAN): Results of a Worldwide Collaboration Study
Omer Karadag¹, Shunsuke Furuta ², Alojzija Hocevar ³, Ummugulsum Gazel ⁴, Andrea Hinojosa-Azaola ⁵, Serdal Ugurlu ⁶, Seerapani Gopaluni ⁷, Ertugrul Cagri Bolek ⁸, Berkan Armagan ⁹, Fatma Alibaz-Oner ¹⁰, Matija Tomšič ¹¹, Gizem Ayan ¹², Ayten Yazici ¹³, Eduardo Martin-Nares ¹⁴, Susy Marcela Sánchez-Cubías ⁵, Mehmet Nedim Tas ¹⁵, Ayşe Cefle ¹⁶, Kenan Aksu ¹⁷, Hajime Kono ¹⁸, Tamihiro Kawakami ¹⁹, Yoshiyuki Abe ²⁰, Timuçin Kaşifoğlu ²¹, Mehmet Engin Tezcan ²², Onay Gercik ²³, Sadettin Kilickap ²⁴, Haner Direskeneli ²⁵, Seza Ozen ²⁶, Ali İhsan Ertenli ⁸ and David Jayne ⁷, ¹Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey, ²Department of Alergy and Immunology, Chiba University Hospital, Chiba, Japan, Chiba, Japan, ³Department of Rheumatology, University Medical Center Ljubljana, Slovenia, LJUBLJANA, Slovenia, ⁴Marmara University, Faculty of Medicine, Department of Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ⁵Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Mexico City, Mexico, ⁶Istanbul University - Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, istanbul, Turkey, ⁷Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁸Hacettepe University Vasculitis Centre, Ankara, Turkey, ankara, Turkey, ⁹Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ¹⁰Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey, ¹¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, LJUBLJANA, Slovenia, ¹²University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, Canada, ¹³Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, ¹⁴Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹⁵Ege University, Faculty of Medicine, Department of Rheumatology, Izmir, Turkey, Izmir, Turkey, ¹⁶Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ¹⁷Ege University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁸Teikyo University School of Medicine, Tokyo, Japan, ¹⁹Department of Dermatology, Tohoku Medical and Pharmaceutical University, Japan, Tohoku, Japan, ²⁰Department of Rheumatology, Juntendo University, Tokyo, Japan, Tokyo, Japan, ²¹Eskişehir Osmangazi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskişehir, Turkey, ²²Department of Rheumatology, Kartal Dr. Lutfi Kirdar Training and Research Hospital , Istanbul, Turkey, Istanbul, Turkey, ²³Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²⁴Hacettepe University, Faculty of Medicine, Department of Preventive Oncology, Ankara, Turkey, Ankara, Turkey, ²⁵Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁶Hacettepe University Hospital, Ankara, Turkey
Background/Purpose: Polyarteritis nodosa (PAN) is a rare type of the systemic vasculitides with heterogeneous presentations.There is a paucity of information on the current phenotypes, ethnic and…
Abstract Number: 1767 • 2018 ACR/ARHP Annual Meeting
Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis
Vanessa L. Kronzer¹, Daniel Larson², Cynthia S. Crowson^3,4, Kenneth J. Warrington⁵, Steven R. Ytterberg⁵, Ashima Makol⁴ and Matthew J. Koster⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pathology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: This study aimed to characterize the presenting features and outcomes of patients with small- or medium-vessel vasculitis and gastrointestinal perforation. Methods: Using a retrospective…
Abstract Number: 1884 • 2018 ACR/ARHP Annual Meeting
Clinical Features and Outcome of Patients with Polyarteritis Nodosa – a Global Collaborative Study
Omer Karadag^1,2, Shunsuke Furuta³, Alojzija Hočevar⁴, Ummugulsum Gazel⁵, Seerapani Gopaluni⁶, Berkan Armagan¹, Matija Tomsic⁷, Fatma Alibaz-Oner⁸, Ihsan Ertenli¹, Seza Ozen¹ and David Jayne², ¹Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ²Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, ³Chiba University Hospital, Chiba, Japan, ⁴Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁵Rheumatology, Marmara University faculty of Medicine, Istanbul, Turkey, ⁶Medicine, University of Cambridge, Cambridge, United Kingdom, ⁷Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸Department of Rheumatology, Marmara University, Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Polyarteritis nodosa (PAN) is a rare subgroup of the primary systemic vasculitides. Furthermore, various subgroups of PAN have been described, such as hepatitis B…
Abstract Number: 2790 • 2018 ACR/ARHP Annual Meeting
Screening of Patients with Adult-Onset Idiopathic Polyarteritis Nodosa for Deficiency of Adenosine Deaminase 2
Oskar Schnappauf¹, Monique Stoffels², Ivona Aksentijevich², Daniel L. Kastner², Peter C. Grayson³, David Cuthbertson⁴, Simon Carette⁵, Sharon A. Chung⁶, Lindsy J. Forbess⁷, Nader A. Khalidi⁸, Curry L. Koening⁹, Carol Langford¹⁰, Carol A. McAlear¹¹, Paul A. Monach¹², Larry W. Moreland¹³, Christian Pagnoux¹⁴, Philip Seo¹⁵, Jason Springer¹⁶, Antoine G. Sreih¹⁷, Kenneth J. Warrington¹⁸, Steven R. Ytterberg¹⁸ and Peter A. Merkel¹⁹, ¹NHGRI, National Institutes of Health, Bethesda, MD, ²Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ⁴Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Russell/Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatology, McMaster University, Hamilton, ON, Canada, ⁹Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁰Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁴Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁵Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁶Department of Internal Medicine, The University of Kansas Medical Center, Division of Allergy, Clinical Immunology & Rheumatology, Kansas City, KS, ¹⁷Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ¹⁹Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is the first described type of monogenic vasculitis. Patients usually present in childhood, but age of onset, disease…
Abstract Number: 824 • 2018 ACR/ARHP Annual Meeting
Comparing Childhood- Versus Adult-Onset Polyarteritis Nodosa
Michele Iudici¹, Pierre Quartier², Christian Pagnoux³, Etienne Merlin⁴, Christian Agard⁵, Achille Aouba⁶, Pascal Roblot⁷, Pascal Cohen¹, Benjamin Terrier¹, Luc Mouthon¹, Loïc Guillevin¹ and Xavier Puéchal¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²AP-HP, Institut des Maladies Génétiques (IMAGINE), and Université Paris-Descartes, Necker-Enfants Malades Hospital, Paris, France, ³Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁴CHU, Clermont-Ferrand, France, ⁵Nantes Hôtel Dieu, Nantes, France, ⁶Caen, Caen, France, ⁷CHU, Poitiers, France
Background/Purpose: To investigate differences between childhood (cPAN)- and adult-onset polyarteritis nodosa (aPAN) patients. Methods: cPAN patients’ clinical findings at onset and outcomes were compared to…
Abstract Number: 2749 • 2017 ACR/ARHP Annual Meeting
Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries
Tsuyoshi Shirai¹, Hiroshi Fujii¹, Yoko Fujita², Yuko Shirota¹, Tomonori Ishii¹ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Polyarteritis nodosa (PAN) is a necrotizing arteritis of medium and small arteries. PAN is divided into systemic and cutaneous PAN (cPAN). cPAN can be…
Abstract Number: 864 • 2015 ACR/ARHP Annual Meeting
Anticytokine Autoantibody Profiling in Five Types of Systemic Vasculitis
Sarthak Gupta^1,2, Seema K. Patel², Mary Blake², Massimo G. Gadina², Wanxia L. Tsai², Simon Carette³, David Cuthbertson⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁵, Carol A. McAlear⁸, Larry W. Moreland⁹, Paul A. Monach¹⁰, Christian Pagnoux³, Philip Seo¹¹, Ulrich Specks¹², Antoine G. Sreih¹³, Steven R. Ytterberg¹⁴, Sarah K. Browne^1,15, Steven M. Holland¹, Mariana J. Kaplan², Peter A. Merkel¹⁶, Peter C. Grayson² and Vasculitis Clinical Research Consortium, ¹Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶Division of Rheumatology, St. Joseph’s Health Care, McMaster University, Hamilton, ON, Canada, ⁷Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁰Rheumatology, Boston University School of Medicine, Boston, MA, ¹¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹³Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁵Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, ¹⁶Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Anticytokine autoantibodies (ACAs) are pathogenic in many hematologic, pulmonary and infectious diseases. Evaluation in autoimmune diseases, including systemic lupus erythematosus (SLE), shows that ACAs…
Abstract Number: 3033 • 2015 ACR/ARHP Annual Meeting
Polyarteritis Nodosa and Cutaneous Arteritis: Are They Distinct Diseases?
Fatma Alibaz-Oner¹, Matthew J. Koster², Cynthia S. Crowson³, Ashima Makol², Steven R. Ytterberg², Eric L. Matteson² and Kenneth J. Warrington², ¹Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis predominantly targeting medium-sized visceral arteries. Cutaneous arteritis (CA) is generally limited to the medium-sized vessels…
Abstract Number: 1782 • 2014 ACR/ARHP Annual Meeting
Long-Term Follow-up of Non-HBV Polyarteritis Nodosa and Microscopic Polyangiitis with Poor-Prognosis Factors
Maxime Samson¹, Xavier Puéchal², Hervé Devilliers³, Pascal Cohen², Boris Bienvenu⁴, Kim Heang Ly⁵, Alain Bruet⁶, Brigitte Gilson⁷, Marc Ruivard⁸, Edouard Pertuiset⁹, Mohamed Hamidou¹⁰, Benjamin Terrier², Christian Pagnoux¹¹, Luc Mouthon², Loic Guillevin¹² and The French Vasculitis Study Group (FVSG)¹², ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ³Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ⁴Médecine interne, CHU Côte de Nacre, CAEN, France, ⁵CHU Dupuytren, Limoges, Limoges, France, ⁶Department of Nephrology and Internal Medicine, CH de Poissy Saint-Germain-en-Laye, Poissy, France, ⁷Department of Nephrology and Internal Medicine, CH de Verdun, Verdun, France, ⁸CHU Estaing, Clermont–Ferrand, Clermont–Ferrand, France, ⁹Rheumatology, René Dubos Hospital, Pontoise, France, ¹⁰CHU Hôtel Dieu, Nantes, Nantes, France, ¹¹Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹²Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose To study the long-term outcomes of 65 patients with non-HBV polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) enrolled in a prospective, randomized, open-label trial,1…
Abstract Number: 808 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Disease Activity in Vasculitis
Alicia Rodriguez-Pla¹, Roscoe L. Warner², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L Koening⁷, Carol A. Langford⁸, Kathleen Maksimowicz-McKinnon⁹, Larry W. Moreland¹⁰, Christian Pagnoux⁴, Philip Seo¹¹, Ulrich Specks^12,13, Kenneth J. Warrington¹⁴, Steven R. Ytterberg¹⁵, Peter A. Merkel¹⁶, Kent J. Johnson², Paul A. Monach¹⁷ and For the Vasculitis Research Consortium¹⁸, ¹Rheumatology, Boston University, Boston, MA, ²Pathology, University of Michigan, Ann Arbor, MI, ³Department of Biostatistics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁶Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Rheumatology, Henry Ford Hospital, Detroit, MI, ¹⁰Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Frederichs Dr NW, Mayo Clinic, Rochester, MN, ¹³Mayo Clinic, Rochester, MN, ¹⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁶University of Pennsylvania, Philadelphia, PA, ¹⁷Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹⁸U Pennsylvania, Philadelphia, PA
Background/Purpose To identify circulating proteins that distinguish between active vasculitis and remission in giant cell arteritis (GCA), Takayasu's arteritis (TAK), polyarteritis nodosa (PAN) and eosinophilic…
Abstract Number: 2642 • 2013 ACR/ARHP Annual Meeting
A Novel Genetic Basis For Systemic Vasculitis: Polyarteritis Nodosa Caused By Recessive Mutations In An Immune-Related Gene
Reeval Segel^1,2, Pnina Elkan-Navon³, Sarah B. Pierce⁴, Tom Walsh⁴, Judith Barash⁵, Shay Padeh⁶, Avraham Zlotogorski⁷, Yackov Berkun⁸, Isabel Voth⁹, Philip Hashkes¹⁰, Liora Harel¹¹, Eduard Ling¹², Fatos Yalcinkaya¹³, Ozgur Kasapcopur¹⁴, Paul F. Renbaum¹⁵, Ariella Weinberg-Shukron¹⁵, Barbara Schormair¹⁶, Mordechai Shohat¹⁷, Alan A. Rubinow¹⁸, Elon Pras¹⁹, Juliane Winkelmann²⁰, Mustafa Tekin²¹, Yair Anikster²², Mary-Claire King⁴ and Ephrat Levy-Lahad¹⁵, ¹Medical Genetics and Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel, ²Hebrew University Medical School, Jerusalem, Israel, ³Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel, ⁴Medical Genetics, University of Washington, Seattle, WA, ⁵Pediatric Day Care, Kaplan Medical Center, Rehovot, Israel, ⁶Pediatrics, Sheba Medical Center, Ramat Gan, Israel, ⁷Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ⁸Pediatrics, Hadassah Medical Center, Mount Scopus, Jerusalem, Israel, ⁹Department of Neurology, Technische Universitat Munchen Klinikum rechts der Isar, Munich, Germany, ¹⁰Pediatric Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ¹¹Pediatric Rheumatology unit, Schneider Children's Medical Center, Tel Aviv University, Petach Tikvah, Israel, ¹²Rheumatology Unit, Soroka University Medical Center and Ben-Gurion University, Beer-Sheva, Beer Sheva, Israel, ¹³Pediatric Nephrology and Rheumatology, Ankara University, Ankara, Turkey, ¹⁴Ankara University, Ankara, Turkey, ¹⁵Medical Genetics, Shaare Zedek Medical Center, Jerusalem, Israel, ¹⁶Helmholtz Zentrum Munchen, Munich, Germany, ¹⁷Rafael Recanati medical genetics Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikvah, Israel, ¹⁸Hadassah Medical Center, Jerusalem, Israel, ¹⁹Institute of Human Genetics, Sheba Medical Center, Ramat Gan, Israel, ²⁰Genetics, Stanford University, San Francisco, CA, ²¹Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, ²²Metabolic Disease Unit, Sheba Medical Center, Ramat Gan, Israel
Background/Purpose: Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis. Disease pathogenesis and possible genetic factors are poorly understood. We identified familial, mostly pediatric PAN, in…
Abstract Number: 1545 • 2012 ACR/ARHP Annual Meeting
Long-Term Follow-up of 118 Polyarteritis Nodosa and Microscopic Polyangiitis without Poor-Prognosis Factors
Maxime Samson¹, Xavier Puechal², Hervé Devilliers³, Camillo Ribi⁴, Pascal Cohen⁵, Boris Bienvenu⁶, Christian Pagnoux⁷, Luc Mouthon⁸, Loic Guillevin⁹ and French Vasculitis Study Group FVSG¹⁰, ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Internal Medicine, Hôpital Cochin, Paris, France, ³Internal medicine, Hôpital Général, Dijon, France, ⁴Internal Medicine, Hôpital Universitaire Cantonal de Genève, Geneve, Switzerland, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁶Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ⁸Internal Medicine, Hopital Cochim, Paris, France, ⁹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ¹⁰Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France
Background/Purpose: Polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA) are 2 vasculitides characterized by necrotizing inflammation of the vessel wall. They share several clinical features and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].